Akeso tetrabody. AK104 introduces novel T cell targeting MOAs that may provide an improved therapeutic index and a favorable toxicity profile when compared to the PD-1 and CTLA-4 combinations. Feb 28, 2024 · Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug to the market. , is designed to achieve preferential binding to tumor infiltrating lymphocytes rather than normal peripheral tissue lymphocytes. Sep 8, 2024 · Second, Akeso’s proprietary Tetrabody technology, which produces antibodies with four antigen-binding sites, can create a very stable structure that enables a “collaborative binding” to Apr 25, 2025 · This milestone marks penpulimab-kcqx as Akeso's first internally developed innovative biologic to receive FDA approval. The approval underscores the robust clinical research behind penpulimab-kcqx and marks Akeso’s successful entry into the United States regulatory system for the first time. Nov 7, 2023 · Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug to the market. Sep 8, 2024 · Second, Akeso’s proprietary Tetrabody technology, which produces antibodies with four antigen-binding sites, can create a very stable structure that enables a “collaborative binding” to Aug 13, 2020 · Based on Akeso's proprietary "TETRABODY" technology, AK104 can simultaneously targets two immune checkpoint molecules: PD-1 and CTLA-4. Jun 1, 2024 · The encouraging results of HARMONi-A and HARMONi-2 trials marked the second success of Akeso’s Tetrabody bispecific platform after the PD-1/CTLA-4 bispecific cadonilimab. Mar 30, 2025 · Akeso's Bispecific Antibody Clinical Portfolio Continues to Expand, Demonstrating Global Leadership in Next-Generation Tumor Immunotherapy In 2024, Akeso continued to focus and make progress on Mar 30, 2025 · Akeso Inc. Aug 5, 2025 · Akeso Biopharma is a private biotech company dedicated to discovering, developing, manufacturing, and commercializing first-in-class and best-in-class antibody therapies for cancer, autoimmune, and metabolic diseases. AK104 is a tetravalent bispecific human IgG1 antibody, targeting two clinically validated receptors, PD-1 and CTLA-4. Oct 1, 2019 · This bispecific antibody is designed based on Akeso Tetrabody platform (AACR, 2018). This bispecific antibody is designed based on Akeso Tetrabody platform (AACR, 2018). HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization. . Founder, president & CEO of Akeso, Inc. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, NDAs for 4 drugs and 6 indications accepted, and 13 ongoing Phase III studies. Since our establishment, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and have established a research and development innovation system encompassing core technologies such as Tetrabody BsAb development technology, ADC technology, SiRNA,mRNA technology and cell therapy technology,a GMP-compliant Jun 1, 2024 · The encouraging results of HARMONi-A and HARMONi-2 trials marked the second success of Akeso’s Tetrabody bispecific platform after the PD-1/CTLA-4 bispecific cadonilimab. , Dr. (9926. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug to the market. Xia Yu said, “Cadonilimab is developed by scientists at Akeso with years of dedication. Aug 14, 2020 · AK104 is a potential next-generation, first-in-class humanized IgG1 tetrameric bi-specific antibody drug candidate that is developed in house by Akeso,Inc. It is a bi-specific antibody new drug with global patent that targets simultaneously PD-1/CTLA-4 and also the first PD-1 based bi- specific antibody drug in the world to submit new drug application. This achievement highlights the company’s innovative drug development capabilities and its Aug 13, 2020 · Based on Akeso's proprietary "TETRABODY" technology, AK104 can simultaneously targets two immune checkpoint molecules: PD-1 and CTLA-4. Nov 27, 2023 · Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Tetrabody technology is a proprietary technology independently developed by Akeso for the design and manufacture of innovative tetravalent bispecific antibodies. owi qhb kwj oqc znh oou hrb izp akw ecs aeu gkk wbp qze osw